512
Participants
Start Date
April 30, 2004
Study Completion Date
February 28, 2005
Atorvastatin
Atorvastatin calcium 10, 20, 40, or 80 mg tablets (dose dependent on individual risk factors and baseline LDL-C level) once daily for 4 weeks. After 4 weeks of treatment, subjects who did not achieve the LDL-C target goal were up-titrated to 20, 40, or 80 mg and subjects who achieved their LDL-target goal remained on the same dose for the following 4 weeks.
Atorvastatin
Atorvastatin calcium 10, 20, 40, or 80 mg tablets (dose dependent on individual risk factors and baseline LDL-C level) once daily for 4 weeks. After 4 weeks of treatment, subjects who did not achieve the LDL-C target goal were up-titrated to 20, 40, or 80 mg and subjects who achieved their LDL-target goal remained on the same dose for the following 4 weeks.
Atorvastatin
Atorvastatin calcium 10, 20, 40, or 80 mg tablets (dose dependent on individual risk factors and baseline LDL-C level) once daily for 4 weeks. After 4 weeks of treatment, subjects who did not achieve the LDL-C target goal were up-titrated to 20, 40, or 80 mg and subjects who achieved their LDL-target goal remained on the same dose for the following 4 weeks.
Pfizer Investigational Site, Dtto. Federal
Pfizer Investigational Site, Caracas
Pfizer Investigational Site, Caracas
Pfizer Investigational Site, Caracas
Pfizer Investigational Site, Caracas
Pfizer Investigational Site, Chihuahua City
Pfizer Investigational Site, Durango
Pfizer Investigational Site, Guadalajara
Pfizer Investigational Site, Zapopan
Pfizer Investigational Site, Monterrey
Pfizer Investigational Site, Monterrey
Pfizer Investigational Site, Belo Horizonte
Pfizer Investigational Site, São Paulo
Pfizer Investigational Site, Santiago
Pfizer Investigational Site, Bogota
Pfizer Investigational Site, Bogotá
Pfizer Investigational Site, Barranquilla
Pfizer Investigational Site, Bogotá, C/marca
Pfizer Investigational Site, Cali, Valle
Pfizer Investigational Site, Quito
Pfizer Investigational Site, Panama City
Pfizer Investigational Site, Curitiba
Pfizer Investigational Site, Porto Alegre
Pfizer Investigational Site, Porto Alegre
Pfizer Investigational Site, São José
Pfizer Investigational Site, São Paulo
Pfizer Investigational Site, Campinas
Pfizer Investigational Site, Campinas
Pfizer Investigational Site, São José do Rio Preto
Pfizer Investigational Site, São Paulo
Pfizer Investigational Site, São Paulo
Pfizer Investigational Site, Rio de Janeiro
Pfizer Investigational Site, Guatemala City
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
INDUSTRY